Search Within

Jose T Baselga

Formats
  1. Meeting Abstract (241)
  2. Journal Article (233)
  3. Conference Paper (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)

More Groups

People
  1. David Hyman (68)
  2. Maurizio Scaltriti (63)
  3. Clifford Hudis (57)
  4. Michael Berger (56)
  5. Larry Norton (51)
  6. Sarat Chandarlapaty (48)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (25)
  4. 2018 (58)
  5. 2017 (68)
  6. 2016 (67)

More Years

Publications
  1. Cancer Research (109)
  2. Journal of Clinical Oncology (92)
  3. Annals of Oncology (29)
  4. Clinical Cancer Research (29)
  5. European Journal of Cancer (25)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (163)
  2. American Society of Clinical Oncology (97)
  3. Oxford University Press (41)
  4. Elsevier Inc. (39)
  5. Nature Publishing Group (30)
  6. Springer (16)

More Publishers

Results (484)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • SANDPIPER: Phase III study of the PI3-kinase inhibitor taselisib (GDC-0032) plus fulvestrant in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer enriched for patients with PIK3CA-mutant tumors
    Meeting Abstract

    Baselga, J.; Cortés, J.; De Laurentiis, M.; Diéras, V.; Harbeck, N.; Hsu, J.; Jin, H.; Schimmoller, F.; Wilson, T. R.; Im, Y. H.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Efficacy and gene expression results from eribulin SOLTI1007 neoadjuvant study
    Meeting Abstract

    Prat, A.; Ortega, V.; Paré, L.; Galván, P.; Oliveira, M.; Nucíforo, P.; Lluch, A.; Morales, S.; Amillano, K.; Lopez, R.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • PARP1/2 inhibition in a subset of triple negative breast cancer (TNBC) patient-derived tumor xenografts (PDX) identifies predictive biomarkers of response
    Meeting Abstract

    Serra, V.; Cruz, C.; Bruna, A.; Ibrahim, Y. H.; Vivancos, A.; Vivancos, A.; Nuciforo, P.; Bellet, M.; Gómez, P.; Pérez, J. M.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • PARP inhibition in breast and ovarian patient-derived tumor xenografts (PDX) harboring germline BRCA1/2 mutations unveils mechanisms of primary and acquired resistance that restore homologous recombination (HR)
    Meeting Abstract

    Cruz, C.; Bustos, L.; Gris, A.; Palafox, M.; Castroviejo, M.; Llop, A.; Morancho, B.; Diez, O.; Gutiérrez, S.; Caratú, G.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Trastuzumab emtansine improves overall survival versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer: Final results from the phase 3 EMILIA study
    Meeting Abstract

    Diéras, V.; Miles, D.; Verma, S.; Pegram, M.; Welslau, M.; Baselga, J.; Krop, I.; Blackwell, K.; Kang, B.; Xu, J.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Phase II, randomized, parallel-cohort study of neoadjuvant buparlisib (BKM120) in combination with trastuzumab and paclitaxel in women with HER2-positive, PIK3CA mutant and PIK3CA wild-type primary breast cancer - NeoPHOEBE
    Meeting Abstract

    Loibl, S.; de la Pena, L.; Nekljudova, V.; Zardavas, D.; Michiels, S.; Denkert, C.; Rezai, M.; Bermejo, B.; Lee, S. C.; Turri, S.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial
    Journal Article

    Bonner, J. A.; Giralt, J.; Harari, P. M.; Baselga, J.; Spencer, S.; Bell, D.; Raben, D.; Liu, J.; Schulten, J.; Ang, K. K.; more...
    European Journal of Cancer (2016)

    Fulltext@MSK | Save
  • Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer
    Journal Article

    Herrera-Abreu, M. T.; Palafox, M.; Asghar, U.; Rivas, M. A.; Cutts, R. J.; Garcia-Murillas, I.; Pearson, A.; Guzman, M.; Rodriguez, O.; Grueso, J.; more...
    Cancer Research (2016)

    Fulltext@MSK | Save
  • Pharmacology in the era of targeted therapies: The case of PI3K inhibitors
    Journal Article

    Toska, E.; Baselga, J.
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save
  • Taselisib (GDC-0032), a potent β-sparing small molecule inhibitor of PI3K, radiosensitizes head and neck squamous carcinomas containing activating PIK3CA alterations
    Journal Article

    Zumsteg, Z. S.; Morse, N.; Krigsfeld, G.; Gupta, G.; Higginson, D. S.; Lee, N. Y.; Morris, L.; Ganly, I.; Shiao, S. L.; Powell, S. N.; more...
    Clinical Cancer Research (2016)

    Fulltext@MSK | Save